Foundation Medicine

Foundation Medicine CEO Michael Pellini

The biotech: Foundation Medicine
Round: $42.5 million
Based: Cambridge, MA
CEO: Michael Pellini
Investors: F. Hoffmann-La Roche, Google Ventures, Kleiner Perkins Caufield & Byers, Third Rock Ventures, Undisclosed Investor, Undisclosed Investor, Undisclosed Investor, Undisclosed Investor

The scoop: The day after we named Foundation Medicine to this year's list of Fierce 15 companies, CEO Michael Pellini unveiled a hefty new round designed to back its commercialization work on FoundationOne, its diagnostic test on the market to evaluate solid tumors. And it has an A-list of drug developers on its partnership roster, putting its technology to work to select ideal patient populations for clinical studies. Only 2 years old, this company is growing fast. And it has some of the coolest venture groups in the business backing its work.

For more:
Special Report: Foundation Medicine - 2012 Fierce 15
Foundation Medicine hauls in $42.5M round to back commercialization effort
Fledgling Foundation Medicine scores a coup with Novartis R&D pact
Foundation Medicine raises $33.5M in expanded Series A

Foundation Medicine
Read more on

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.

A Cedars-Sinai team used stem cells to uncover a key mechanism of young onset Parkinson's, as well as a potential remedy—an existing skin treatment.